{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:30:44Z","timestamp":1792888244998,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ctro.2024.100843","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T23:41:37Z","timestamp":1723851697000},"page":"100843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials"],"prefix":"10.1016","volume":"49","author":[{"given":"Rachel M.","family":"Glicksman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Vesprini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Szumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley K.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Lin","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Deabreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mamedov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2024.100843_b0005","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is \u03b1\/\u03b2 for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100843_b0010","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2017.12.011","article-title":"Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: A meta-analysis of randomized trials","volume":"100","author":"Vogelius","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100843_b0015","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 chhip trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2024.100843_b0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.304","article-title":"10-year efficacy and co-morbidity outcomes of a phase iii randomised trial of conventional vs. Hypofractionated high dose intensity modulated radiotherapy for prostate cancer (chhip; cruk\/06\/016)","volume":"41","author":"Syndikus","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100843_b0025","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100843_b0030","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100843_b0035","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the hypo-rt-pc randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2024.100843_b0040","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.027","article-title":"5-year outcomes from pace b: An international phase iii randomized controlled trial comparing stereotactic body radiotherapy (sbrt) vs. Conventionally fractionated or moderately hypo fractionated external beam radiotherapy for localized prostate cancer","volume":"117","author":"van As","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100843_b0045","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ijrobp.2016.06.2455","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the getug-01 randomized study","volume":"96","author":"Pommier","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100843_b0050","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1200\/JCO.2006.10.5171","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of getug-01","volume":"25","author":"Pommier","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100843_b0055","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2003.05.004","article-title":"Phase iii trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation therapy oncology group 9413","volume":"21","author":"Roach","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100843_b0060","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (nrg\/rtog 9413): Long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2024.100843_b0065","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ijrobp.2023.07.003","article-title":"Elective nodal irradiation: Old game, new sport","volume":"117","author":"Vesprini","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100843_b0070","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (pop-rt): Outcomes from phase iii randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2024.100843_b0075","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.ijrobp.2023.09.053","article-title":"Safety of ultrahypofractionated pelvic nodal irradiation in the definitive management of prostate cancer: Systematic review and meta-analysis","volume":"118","author":"Mohamad","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100843_b0080","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ijrobp.2023.02.054","article-title":"A randomized feasibility trial of stereotactic prostate radiation therapy with or without elective nodal irradiation in high-risk localized prostate cancer (sport trial)","volume":"117","author":"Houlihan","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100843_b0085","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.37165","article-title":"Differential use of radiotherapy fractionation regimens in prostate cancer","volume":"6","author":"Qureshy","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ctro.2024.100843_b0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.08.002","article-title":"Rtog gu radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer","volume":"74","author":"Lawton","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100843_b0095","article-title":"Randomized trial of concomitant hypofractionated imrt boost versus conventional fractionated imrt boost for localized high-risk prostate cancer (phart2-rct)","author":"Glicksman","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100843_b0100","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","article-title":"Phase 1\u20132 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (saturn): Early toxicity and quality of life","volume":"102","author":"Musunuru","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100843_b0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijrobp.2019.12.044","article-title":"Evaluating the tolerability of a simultaneous focal boost to the gross tumor in prostate sabr: A toxicity and quality-of-life comparison of two prospective trials","volume":"107","author":"Alayed","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100843_b0110","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13014-015-0426-4","article-title":"Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated stereotactic ablative body radiotherapy (sabr)","volume":"10","author":"Nicolae","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2024.100843_b0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0360-3016(94)90138-4","article-title":"Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and gleason score in men with clinically localized prostate cancer","volume":"28","author":"Roach","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2024.100843_b0120","doi-asserted-by":"crossref","first-page":"S770","DOI":"10.1016\/S0167-8140(23)08750-9","article-title":"Oc-0924 prostate rt in high risk or n+ moderate vs extreme hypofractionation (prime): An interim analysis","volume":"182","author":"Murthy","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2024.100843_b0125","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (pace-b): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2024.100843_b0130","doi-asserted-by":"crossref","first-page":"e034623","DOI":"10.1136\/bmjopen-2019-034623","article-title":"Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (prime trial)","volume":"10","author":"Murthy","year":"2020","journal-title":"BMJ Open"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824001204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630824001204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T13:49:22Z","timestamp":1730555362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630824001204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":26,"alternative-id":["S2405630824001204"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100843","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2024.100843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100843"}}